- Does Prostate Cancer belong to Family Inherited Tumors?
- The most dangerous breast cancer: 3-year overall survival rate of combined immunotherapy before surgery is 95.2%
- Sanofi oral SERD failed: Only one ADC in the phase 3 tumor pipeline
- The most expensive drug ever: FDA approves gene therapy priced at $2.8 million
- WHO renames monkeypox virus to avoid negative impact on monkeys
- New hope for Paralysis: A man wears brain-computer interface for seven years
Moderna latest paper: Evaluation of the safety and efficacy of mRNA vaccine as a booster shot
- 14 hospitals in Japan issued a “blood warning”
- Oxford study finds increased risks of dementia two years after contracting COVID-19
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Taiwan death from COVID-19 vaccination exceeds death from COVID-19
- The world top 5 best-selling drugs in 2020
Moderna: Evaluation of safety and efficacy of mRNA vaccine as booster shot.
A new wave of new coronaviruses caused by the more transmissible and higher viral load of the Delta mutant strain is exacerbating the global public health crisis, and many studies have shown that the ability of existing vaccines to prevent the Delta mutant strain has declined.
Therefore, Re-inoculation of booster shots for people who have been vaccinated against the COVID-19 vaccine has become a potential demand for responding to the current COVID-19 pandemic.
On September 15, 2021, Moderna’s researchers published a paper titled: Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis in the sub-Journal Nature Medicine.
This vaccination study carried out on 80 people showed that Moderna’s mRNA-1273 vaccine and the improved vaccine against variant strains are safe and well tolerated as booster needles, and can improve the key to focus on the new coronavirus variant strains (including Beta, Gamma, Delta variants) neutralizing antibody levels.
In order to evaluate the safety and efficacy of the booster shot of the COVID-19 vaccine, the researchers asked subjects who had received two shots of the Moderna vaccine (mRNA-1273) to receive a booster shot 6 months later. Their booster shots were either the original vaccine or an improved vaccine against variant strains, such as the mRNA-1273.211 vaccine against multiple variant strains.
Darin Edwards and colleagues observed four booster injection groups (20 subjects in each group, and the injected vaccine was a different combination of original and modified vaccines). Immediately before the booster shot, the level of SARS-CoV-2 neutralizing antibodies in the subjects’ blood was lower than their level one month after the second shot, and it was targeted at the mutant strains Beta, Gamma, and Delta. Neutralizing antibody levels are either very low or undetectable.
The authors found that the three booster injections they tested can make the subjects’ SARS-CoV-2 neutralizing antibody titers higher than the level one month after the first round of vaccines, caused by mRNA-1273 and mRNA-1273.211 The increase is particularly significant. In addition, all three boosters can increase the neutralizing antibody titers against Beta, Gamma, Delta variants and other variants that require attention.
The authors of the paper stated that the preliminary analysis still has some limitations, including the small sample size and the fact that the treatment groups on which the results are based are not randomly assigned. However, they believe that the mRNA technology platform for the test for SARS-CoV-2 mutant strains that needs to be tested seems to be effective in enhancing needle research and development.
(source:internet, reference only)